Emergent BioSolutions announced that it has entered into an agreement to acquire Adapt Pharma and its flagship product NARCAN (naloxone HCl) Nasal Spray, the first and only needle-free formulation of naloxone approved by the U.S. Food and Drug Administration (FDA) and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.
Upon the closing of the transaction, Emergent will acquire the NARCAN Nasal Spray product and a development pipeline of new treatment and delivery options to address opioid overdose, and bring on approximately 50 employees, located in the USA, Canada, and Ireland, including those responsible for supply chain management, research and development, government affairs, and commercial operations. The total consideration for the transaction is up to $735 million.
Emergent BioSolutions is a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland (USA). It develops vaccines and antibody therapeutics for infectious diseases, oncology and autoimmune disorders, and provides medical devices for biodefense purposes.